Skip to main content
. 2020 Jul 20;8(1):e001321. doi: 10.1136/bmjdrc-2020-001321

Table 1.

Baseline characteristics of the analyzed population

Characteristics Total
n=673
Incident type 2 diabetes Incident (pre)diabetes
No
n=586
Yes
n=68
P value* No
n=372
Yes
n=130
P value*
Variables measured at baseline (F4)
 Age (years)† 60.6±5.6 60.3±5.5 63.1±5.3 <0.001 59.9±5.6 61.0±5.2 0.030
 Sex male, n (%) 328 (48.7) 282 (48.1) 41 (60.3) 0.076 154 (41.4) 78 (60.0) <0.001
 Height (cm)† 168.1±8.9 168.2±8.9 168.3±8.8 0.778 167.8±8.9 168.3±8.4 0.339
 Waist circumference (cm)† 94.2±13.3 93.5±13.3 102.1±11.2 <0.001 90.6±11.7 97.7±11.1 <0.001
 Triglycerides (mmol/L)‡ 1.26 (1.02) 1.23 (1.05) 1.63 (1.15) <0.001 1.13 (1.07) 1.35 (1.12) 0.001
 Total cholesterol/HDL† 4.15±1.1 4.11±1.12 4.70±1.17 <0.001 3.92±1.08 4.44±1.14 <0.001
 Hypertension, n (%) 266 (39.5) 221 (37.7) 40 (58.8) 0.001 114 (30.6) 63 (48.5) <0.001
 Smoking status, n (%) 0.103 0.536
  Never 295 (43.8) 248 (42.3) 38 (55.9) 156 (41.9) 60 (46.2)
  Former 287 (42.7) 258 (44) 23 (33.8) 164 (44.1) 50 (38.5)
  Current 91 (13.5) 80 (13.7) 7 (10.3) 52 (14.0) 20 (15.4)
 Alcohol intake, n (%) 0.976 0.798
  0 g/day 185 (27.5) 159 (27.1) 19 (27.9) 103 (27.7) 40 (30.8)
  Men 0.1–39.9 g/day
  Women 0.1–19.9 g/day
344 (51.1) 300 (51.2) 35 (51.5) 192 (51.6) 64 (49.2)
  Men ≥40 g/day
  Women ≥20 g/day
144 (21.4) 127 (21.7) 14 (20.6) 77 (20.7) 26 (20.0)
 Physical activity, n (%) 0.114 0.201
  No activity 170 (25.3) 143 (24.4) 21 (30.9) 83 (22.3) 32 (24.6)
  Low activity 78 (11.6) 65 (11.1) 10 (14.7) 35 (9.4) 19 (14.6)
  Moderate activity 234 (34.8) 203 (34.6) 26 (38.2) 133 (35.8) 47 (36.2)
  High activity 191 (28.4) 175 (29.9) 11 (16.2) 121 (32.5) 32 (24.6)
 Education ≤10 years, n (%) 319 (47.4) 270 (46.1) 41 (60.3) 0.036 166 (44.6) 67 (51.5) 0.208
 High-sensitivity C reactive protein (mg/L)‡ 1.20 (1.04) 1.16 (1.10) 1.77 (1.32) 0.002 0.99 (1.12) 1.53 (1.23) <0.001
 Parental history of diabetes, n (%) 0.104 0.003
  No parent 368 (54.7) 329 (56.1) 28 (41.2) 228 (61.3) 56 (43.1)
  Unknown 134 (19.9) 113 (19.3) 16 (23.5) 60 (16.1) 36 (27.7)
  One parent 155 (23.0) 131 (22.4) 21 (30.9) 76 (20.4) 34 (26.2)
  Both parents 16 (2.4) 13 (2.2) 3 (4.4) 8 (2.2) 4 (3.1)
 MBA† 776±467 758±459 959±483 <0.001 647±426 949±468 <0.001
 RHI† 2.13±0.67 2.17±0.68 1.89±0.55 <0.001 2.23±0.70 2.05±0.63 0.005
 Fasting glucose (mmol/L)† 5.3±0.52 5.3±0.47 5.9±0.55 <0.001 5.1±0.39 5.4±0.37 <0.001
 Fasting insulin (µU/mL)‡ 9.2 (1.02) 8.9 (1.02) 13.1 (1.07) <0.001 8.0 (1.02) 10.3 (1.04) <0.001
 2-hour glucose (mmol/L)† 6.2±1.69 6.0±1.54 8.1±1.77 <0.001 5.4±1.13 6.3±1.0 <0.001
 HOMA-IR‡ 2.16 (1.02) 2.06 (1.02) 3.41 (1.07) <0.001 1.82 (1.03) 2.46 (1.04) <0.001
 HOMA-beta‡ 105 (1.02) 104 (1.02) 114 (1.07) 0.185 102 (1.02) 110 (1.04) 0.102
 HbA1c (mmol/mol)† 36.5±3.53 36.0±3.34 39.6±3.38 <0.001 35.4±3.19 37.2±3.13 <0.001
 HbA1c (%)† 5.5±0.32 5.4±0.29 5.8±0.32 <0.001 5.4±0.28 5.5±0.28 <0.001
Variables measured at follow-up (FF4)
 Fasting glucose (mmol/L)† 5.7±0.81§ 5.5±0.54 6.8±1.52 <0.001 5.3±0.40 6.0±0.58 <0.001
 Fasting insulin (µU/mL)‡ 10.3 (1.02)§ 9.9 (1.05)¶ 14.9 (1.17) <0.001 8.7 (1.05) 13.4 (1.12) <0.001
 2-hour glucose (mmol/L)† 6.7±2.41** 6.3±1.73 12.3±3.44†† <0.001 5.4±1.09 8.5±1.87‡‡ <0.001
 HOMA-IR‡ 2.53 (1.02)§§ 2.41 (1.05)¶ 4.54 (1.20)¶¶ <0.001 2.01 (1.07) 3.54 (1.12)*** <0.001
 HOMA-beta‡ 101 (1.02)§§ 102 (1.05)¶ 99 (1.20)¶¶ 0.862 100 (1.05) 109 (1.12)*** 0.117
 HbA1c (mmol/mol)† 37.1±4.81††† 36.4±3.67 42.8±8.2‡‡‡ <0.001 35.9±3.16 37.9±4.22 <0.001
 HbA1c (%)† 5.6±0.44††† 5.5±0.34 6.1±0.75‡‡‡ <0.001 5.4±0.29 5.6±0.39 <0.001

*For differences between groups: Kruskal-Wallis test for continuous variables; χ² test for categorical variables.

†Continuous variables are presented as arithmetic mean±SD.

‡Natural logarithmic transformed variables are presented as geometric mean (antilog of SE).

§n=671.

¶n=585.

**n=628.

††n=42.

‡‡n=123.

§§n=653.

¶¶n=54.

***n=127.

†††n=672.

‡‡‡n=67.

HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-beta, homoeostasis model assessment of beta-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance; MBA, mean baseline amplitude; RHI, reactive hyperemia index.